33 recruiting. 33 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 33 | Recruiting 33 |
Follow Heart Failure: new trials by email Literature Review of Heart Failure trials Research Report on Heart Failure
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Central Apnea in Heart Failure: Physiological Mechanisms to Inform Treatment Trazodone + positive airway pressure (PAP) therapy, Oxygen + positive airway pressure (PAP) therapy - Sleep Disordered Breathing, Able Bodied | Phase 4 | Recruiting | VA Office of Research and Development | 200 | 2026-09-16 | 2026-10-13 |
| STEPwise De-escalation and Optimizing Withdrawal of ARNI and SGLT2i in Normalized Heart Failure Stepwise Withdrawal of ARNI and SGLT2i, Continued Guideline-Directed Medical Therapy - Heart Failure With Reduced Ejection Fraction, Heart Failure | Phase 4 | Recruiting | Kyungsub Song | 80 | 2026-08-12 | 2026-09-02 |
| Incretin Therapies in Obesity-related HFpEF Tirzepatide - Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction | Phase 4 | Recruiting | Columbia University | 50 | 2026-08-07 | 2026-08-24 |
| The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy - Fontan, Heart Failure | Phase 4 | Recruiting | The University of Hong Kong | 30 | 2026-07-01 | 2026-07-28 |
| Sacubitril-valsartan in Patients With Heart Failure With Reduced Ejection Fraction From Rural Tanzania Sacubitril / Valsartan Oral Tablet - Heart Failure | Phase 4 | Recruiting | Martin Rohacek | 298 | 2026-06-30 | 2026-07-02 |
| Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot Study Sacubitril / Valsartan, SGLT-2 inhibitor, SGLT2 Inhibition - Heart Failure Due to Coronary Artery Disease, Valvular Cardiomyopathy | Phase 4 | Recruiting | Kyungsub Song | 80 | 2026-05-20 | 2026-09-02 |
| Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure Ketone Monoester (KE) - Acute Heart Failure (AHF), Cardiogenic Shock | Phase 4 | Recruiting | Institute for Clinical and Experimental Medicine | 12 | 2026-04-04 | 2026-04-14 |
| Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure Furosemide intravenous solution - Heart Failure, Heart Failure - NYHA II - IV | Phase 4 | Recruiting | Lakeland Regional Health Systems, Inc. | 600 | 2026-04-01 | 2026-04-09 |
| DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis Empagliflozin + Carvedilol, Carvedilol - Cirrhotic Cardiomyopathy, Empagliflozin | Phase 4 | Recruiting | Post Graduate Institute of Medical Education and Research, Chandigarh | 400 | 2026-04-01 | 2026-05-14 |
| Pharmacological Optimization in Prevention in Heart Failure: A Sex-gap? Guideline-Directed Medical Therapy (GDMT) - Heart Failure, Acute Heart Failure | Phase 4 | Recruiting | IRCCS Policlinico S. Donato | 368 | 2026-03-31 | 2026-10-16 |
| The Assessment of Partial Guideline-Directed Medical Therapy Down Titration in Heart Failure in Remission. Down-titration, Continuation of guideline-directed heart failure therapy - Heart Failure | Phase 4 | Recruiting | Ziekenhuis Oost-Limburg | 100 | 2026-03-16 | 2026-04-07 |
| Digoxin After Acute Heart Failure (DIG-DICA) Usual Care, Digoxin - Acute Heart Failure (AHF) | Phase 4 | Recruiting | Hospital General de Agudos "Dr. Cosme Argerich" | 120 | 2025-12-16 | 2026-06-02 |
| Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction GLP-1RA - Heart Failure Preserved Ejection Fraction, Epicardial Adipose Tissue | Phase 4 | Recruiting | University of Virginia | 192 | 2025-11-20 | 2026-08-11 |
| Gator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure Lasix ONYU - Heart Failure, Volume Overload | Phase 4 | Recruiting | University of Florida | 100 | 2025-11-20 | 2026-06-08 |
| Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator Metoprolol Succinate, Carvedilol - Heart Failure With Reduced Ejection Fraction (HFrEF), Sudden Cardiac Death | Phase 4 | Recruiting | University of Rochester | 2000 | 2025-08-17 | 2025-09-18 |
| Effect of Losartan on the Neurohumoral Axis and Ventricular Remodeling of Patients With Severe Aortic Regurgitation Undergoing Valve Surgery. Losartan 50 mg, Placebo - Heart Valve Diseases, Left Ventricle Remodeling | Phase 4 | Recruiting | Vitor Emer Egypto Rosa | 60 | 2025-07-01 | 2025-08-01 |
| Landiolol in Mitral Valve Surgery Landiolol, Placebo - Cardiac Failure, Low Cardiac Output Syndrome | Phase 4 | Recruiting | Università Vita-Salute San Raffaele | 1500 | 2025-01-28 | 2025-12-29 |
| ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement Enavogliflozin, Standard-of-Care - Aortic Valve Stenosis, Heart Failure | Phase 4 | Recruiting | Duk-Woo Park, MD | 1040 | 2024-12-18 | 2026-06-29 |
| A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record Empagliflozin 10 MG, Dapagliflozin 10 MG - Diabetes Mellitus, Type 2, Heart Failure | Phase 4 | Recruiting | Herlev and Gentofte Hospital | 17200 | 2024-10-10 | 2026-09-18 |
| Colchicine in Acutely Decompensated HFREF Colchicine 0.6 mg, Control/Placebo group - Heart Failure, Decompensated Heart Failure | Phase 4 | Recruiting | University of Virginia | 30 | 2024-06-01 | 2024-05-08 |
Showing 20 of 33. Sign in to see all of them.
Heart Failure, Diastolic (4) · Heart Valve Diseases (3) · Cardiomyopathies (2) · Cardiotoxicity (2) · Iron Deficiencies (2) · Ventricular Dysfunction, Left (2) · Anemia, Iron-Deficiency (1) · Aortic Valve Insufficiency (1) · Aortic Valve Stenosis (1) · Arrhythmias, Cardiac (1) · Ascites (1) · Atrial Fibrillation (1) · Breast Diseases (1) · Breast Neoplasms (1)
Cardiovascular Diseases (32) · Heart Diseases (32) · Pathological Conditions, Signs and Symptoms (13) · Pathologic Processes (8) · Nutritional and Metabolic Diseases (5) · Metabolic Diseases (4) · Signs and Symptoms (4) · Aortic Valve Disease (2) · Chemically-Induced Disorders (2) · Chronic Disease (2) · Disease Attributes (2) · Drug-Related Side Effects and Adverse Reactions (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2)
sacubitril and valsartan sodium hydrate drug combination (5) · Furosemide (3) · empagliflozin (3) · Carvedilol (2) · Isosorbide Dinitrate (2) · Sodium-Glucose Transporter 2 Inhibitors (2) · Standard of Care (2) · dapagliflozin (2) · Adrenergic beta-Antagonists (1) · Bumetanide (1) · Colchicine (1) · Digoxin (1) · Enavogliflozin (1) · Hydralazine (1) · Losartan (1)
China-Japan Friendship Hospital (2) · Kyungsub Song (2) · University of Virginia (2) · Charite University, Berlin, Germany (1) · Columbia University (1) · Copenhagen University Hospital, Rigshospitalet (1) · Dinesh Thavendiranathan (1) · Duk-Woo Park, MD (1) · Heart Center Research, LLC (1) · Herlev and Gentofte Hospital (1) · Hospital General de Agudos "Dr. Cosme Argerich" (1) · IRCCS Policlinico S. Donato (1) · Institute for Clinical and Experimental Medicine (1) · Lakeland Regional Health Systems, Inc. (1) · Martin Rohacek (1)
United States (11) · South Korea (4) · China (3) · Italy (3) · Denmark (2) · Poland (2) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Canada (1) · Czechia (1) · Germany (1) · Hong Kong (1) · India (1)
Abdul Parwani, Dr. (1) · Amit Patel, MD (1) · Anas Bizanti, MD (1) · Andrew Lurie, DO (1) · Antonio Abbate, MD (1) · Burkert Pieske, Prof. Dr. (1) · Chih-Cheng Wu, MD. PhD (1) · Donna SH Lin, MD (1) · Elissa A Driggin, MD (1) · Gabriele Masini, MD PhD (1) · Guillermo Ernesto Liniado, MD (1) · Hyung Gon Je, Professor (1) · Jay Dinerman, MD (1) · Jerry D Estep, MD (1) · Johannes Grand, PhD (1)
PMID 10758967, PMID 25176015, PMID 27170530, PMID 27849566, PMID 28476564, PMID 30415601, PMID 30586432, PMID 33016100, PMID 33932120, PMID 35460884, PMID 36356631, PMID 37149565, PMID 37449716, PMID 40855136, PMID 42044762, PMID 42508844
2023 (1), 2025 (1), I01RD001576 (1), K76AG064428 (1)